Labiotech.eu

New weight loss drugs: biotech’s mission to end obesity

Willow Shah-Neville — Tue, 25 Jul 2023 16:22:17 +0000

Obesity has nearly tripled since 1975, becoming an ever-growing health threat. In 2016, it was estimated that more than 1.9 billion adults in the world were overweight, with more than 650 million of those being officially obese. Obesity can be defined as abnormal or excessive fat accumulation that presents a risk to health, with a […]

The post New weight loss drugs: biotech’s mission to end obesity appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Triastek sees positive results from printed oral treatment for ulcerative colitis

Jim Cornall — Tue, 25 Jul 2023 10:22:26 +0000

Triastek, Inc. has completed its first in human study of its third 3D printing drug product, T21, designed to treat moderate to severe ulcerative colitis (UC). Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site – the colon – for the drug release. The administration of […]

The post Triastek sees positive results from printed oral treatment for ulcerative colitis appeared first on Labiotech.eu.

Can the microbiome help the fight against infections?

Jim Cornall — Tue, 25 Jul 2023 09:30:00 +0000

Animals and humans coexist with a vast array of microorganisms known as the microbiome, forming a relationship that can range from mutually beneficial to pathogenic. To safeguard against harmful pathogens and maintain the presence of beneficial microorganisms, animals have evolved various defenses.One is small antimicrobial peptides (AMPs), small peptides that combat invading microbes. AMPs are […]

The post Can the microbiome help the fight against infections? appeared first on Labiotech.eu.

Molecure raises $12M and gets FDA clearance for pulmonary sarcoidosis trial

Jim Cornall — Tue, 25 Jul 2023 09:15:00 +0000

Molecure S.A. has received clearance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application to conduct phase II clinical testing of OATD-01. The announcement follows the company closing a secondary public offering and entering into subscription agreements for all 2,776,000 H-shares offered by way of private placement, within the […]

The post Molecure raises $12M and gets FDA clearance for pulmonary sarcoidosis trial appeared first on Labiotech.eu.

Roche and Alnylam to work on RNAi therapeutic to treat hypertension

Jim Cornall — Tue, 25 Jul 2023 09:00:00 +0000

Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic currently in phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent, preventable risk factor for death and disability, with approximately 80% of the adults with hypertension worldwide not […]

The post Roche and Alnylam to work on RNAi therapeutic to treat hypertension appeared first on Labiotech.eu.

Crescendo Biologics raises $32M and expands cancer trial

Jim Cornall — Tue, 25 Jul 2023 08:21:48 +0000

Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major […]

The post Crescendo Biologics raises $32M and expands cancer trial appeared first on Labiotech.eu.

Sarcoma research: is a breakthrough in sight?

Roohi Mariam Peter — Mon, 24 Jul 2023 14:24:40 +0000

Among the rarest forms of cancers, sarcomas develop in the bones and connective tissues that support structures in the body like blood vessels, nerves and joints. This year, around 13,400 new cases of soft tissue sarcomas are estimated to be diagnosed in the U.S. alone, according to the American Cancer Society. As July marks Sarcoma […]

The post Sarcoma research: is a breakthrough in sight? appeared first on Labiotech.eu.

How AI is shaping clinical research and trials

Willow Shah-Neville — Fri, 21 Jul 2023 10:31:56 +0000

Artificial intelligence (AI) is everywhere at the minute, seemingly being used in some capacity in almost every professional industry, including clinical research and trials. In fact, it is fair to say that AI has taken the biotech industry by storm, and the hype surrounding it has led to numerous AI startup companies coming onto the […]

The post How AI is shaping clinical research and trials appeared first on Labiotech.eu.

Beyond Biotech podcast 55: Inflammasomes

Jim Cornall — Thu, 20 Jul 2023 19:10:00 +0000

This week on our podcast, we’re talking about inflammasome inhibitors with Alan Watt, CEO of NodThera. The company recently announced it is the first to show a reduction in neuroinflammation with an inflammasome inhibitor. NodThera announced positive initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects […]

The post Beyond Biotech podcast 55: Inflammasomes appeared first on Labiotech.eu.

CatalYm shows importance of GDF-15 in tumor immunotherapy resistance

Jim Cornall — Thu, 20 Jul 2023 17:00:00 +0000

CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […]

The post CatalYm shows importance of GDF-15 in tumor immunotherapy resistance appeared first on Labiotech.eu.

Endometrial cancer drug receives breakthrough therapy designation in China

Jim Cornall — Thu, 20 Jul 2023 15:36:06 +0000

HUTCHMED (China) Limited has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based […]

The post Endometrial cancer drug receives breakthrough therapy designation in China appeared first on Labiotech.eu.

Mage Biologics created to develop oral antibody therapy for ulcerative colitis

Jim Cornall — Thu, 20 Jul 2023 15:00:00 +0000

TVM Capital Life Science and specialty pharma company Tillotts Pharma are to jointly invest up to $28 million in a newly formed U.S.-based biotechnology company, Mage Biologics Inc. TVM will invest with its TVM Life Science Innovation II SCSp (TVM LSI II) fund and will provide strategic advice to Mage Bio. Mage Bio is the […]

The post Mage Biologics created to develop oral antibody therapy for ulcerative colitis appeared first on Labiotech.eu.

Seven pharma companies form alliance to prepare for future pandemics

Jim Cornall — Thu, 20 Jul 2023 14:00:00 +0000

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

The post Seven pharma companies form alliance to prepare for future pandemics appeared first on Labiotech.eu.

Biomica announces interim positive results from irritable bowel syndrome program

Jim Cornall — Thu, 20 Jul 2023 10:00:00 +0000

Biomica Ltd., a clinical-stage biopharmaceutical company developing microbiome-based therapeutics, has released interim positive results from pre-clinical studies in its irritable bowel syndrome (IBS) program. The work was performed in collaboration with the lab of Kara Gross Margolis, associate director for clinical and translational research for the New York University Pain Research Center and an associate […]

The post Biomica announces interim positive results from irritable bowel syndrome program appeared first on Labiotech.eu.

Sosei Heptares hails ‘transformational’ acquisition

Jim Cornall — Thu, 20 Jul 2023 09:34:31 +0000

Sosei Group Corporation is set to acquire all shares of Idorsia Pharmaceuticals Japan Ltd (IPJ) and Idorsia Pharmaceuticals Korea Co., Ltd (IPK). The strategic transaction also includes the Japan and APAC territory rights, with the exception of China, to a pipeline of medicines from Idorsia’s portfolio, with lead product PIVLAZ (clazosentan) already commercially available and […]

The post Sosei Heptares hails ‘transformational’ acquisition appeared first on Labiotech.eu.

Genetic engineering giants: is China poised to lead the way?

Willow Shah-Neville — Wed, 19 Jul 2023 15:57:04 +0000

For many people, when they hear China and genetic engineering in the same sentence, it is often synonymous with scandal, and gene-edited babies may spring to mind. And, although it is true that nearly five years ago, researcher He Jiankui infamously claimed he had created the first ever gene-edited babies, before going to prison for […]

The post Genetic engineering giants: is China poised to lead the way? appeared first on Labiotech.eu.

Novel bacterial communication system could help take on antimicrobial resistance

Jim Cornall — Wed, 19 Jul 2023 10:30:00 +0000

A new stress signaling system enables bacteria cells to adapt and protect themselves against the immune system and certain antibiotics. The discovery was made by researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Singapore Centre for Environmental […]

The post Novel bacterial communication system could help take on antimicrobial resistance appeared first on Labiotech.eu.

Moleculin issues acute myeloid leukemia drug data

Jim Cornall — Wed, 19 Jul 2023 09:24:12 +0000

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with drug candidates targeting hard-to-treat tumors and viruses, has published data from its completed MB-105 European phase 1 clinical trial assessing the safety and efficacy of annamycin as a single agent for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). ‘Results of a […]

The post Moleculin issues acute myeloid leukemia drug data appeared first on Labiotech.eu.

Ten years to ten days: French startup revolutionizes early diagnosis of endometriosis with a saliva test

Roohi Mariam Peter — Tue, 18 Jul 2023 11:13:13 +0000

A condition that affects around 190 million women and girls worldwide, according to the World Health Organization, endometriosis is a chronic, difficult-to-treat disease that causes debilitating pelvic pain. Often misdiagnosed as irritable bowel syndrome (IBS) and sometimes dismissed as menstrual cramps, the diagnosis of endometriosis can take around 10 years, raising the severity of the […]

The post Ten years to ten days: French startup revolutionizes early diagnosis of endometriosis with a saliva test appeared first on Labiotech.eu.

Korro Bio and Frequency Therapeutics to merge

Jim Cornall — Tue, 18 Jul 2023 09:47:03 +0000

Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs, is expected to […]

The post Korro Bio and Frequency Therapeutics to merge appeared first on Labiotech.eu.